NSC 617145 |
Catalog No.GC18507 |
NSC 617145 est un inhibiteur sélectif de l'hélicase du syndrome de Werner (WRN) avec une valeur IC50 de 230 nM. NSC 617145 inhibe la WRN ATPase et induit des cassures double brin (DSB) et des anomalies chromosomiques. NSC 617145 montre une sélectivité pour WRN sur les hélicases BLM, FANCJ, ChlR1, RecQ et UvrD.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 203115-63-3
Sample solution is provided at 25 µL, 10mM.
NSC 617145 is an inhibitor of WRN helicase (IC50 = 230 nM) that inhibits the ATPase, but not exonuclease, activity of WRN helicase in a concentration-dependent manner[1] . It is selective for WRN over BLM, FANCJ, ChlR1, RecQ, and UvrD helicases, only exhibiting 7% inhibition of RECQ1 at a concentration of 5 uM. NSC 617145 inhibits growth of HeLa cells via formation of DNA double strand breaks (DSBs) and induction of apoptosis in a WRN helicase-dependent manner. NSC 617145 also acts synergistically with mitomycin C to inhibit growth as well as induce DSBs and chromosomal abnormalities in Fanconia-anemia deficient (FA-D2-/-) cells.
Reference:
[1]. Aggarwal, M., Banerjee, T., Sommers, J.A., et al. Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway. Cancer Res. 73(17), 5497-5507 (2013).
Average Rating: 5
(Based on Reviews and 1 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *